Recent Advances in the Research and Development of RAF Kinase Inhibitors

Title: Recent Advances in the Research and Development of RAF Kinase Inhibitors

Volume: 6 Issue: 11

Author(s): Roger A. Smith, Jacques Dumas, Lila Adnane and Scott M. Wilhelm

Affiliation:

Keywords: Sorafenib, BAY 43-9006, RAF-1, C-RAF, B-RAF, kinase inhibitor, MAP kinase

Abstract: The RAS-RAF-MEK-ERK signaling pathway (ERK pathway) plays a key role in tumorigenesis and cancer progression. Mutations of RAS or B-RAF lead to a constitutive activation of the ERK pathway, which ultimately results in increased cell division, and cell survival. This review article focuses on the recent literature related to ERK pathway inhibitors, with a particular emphasis on RAF kinase inhibitors. Preclinical and clinical data for the RAF kinase inhibitor sorafenib (BAY 43-9006 tosylate), that was recently approved in the US for the treatment of advanced renal cell carcinoma, are also outlined.

Cite this article as:

Smith A. Roger, Dumas Jacques, Adnane Lila and Wilhelm M. Scott, Recent Advances in the Research and Development of RAF Kinase Inhibitors, Current Topics in Medicinal Chemistry 2006; 6 (11) . https://dx.doi.org/10.2174/156802606777812077